oral reversible ERK1/2 kinase inhibitor
combo eff. w/ MEKi in mKRAS model; in Ph. I
from historical kinase sel. data, SBDD + opt.
Mol. Cancer Ther. Dec. 3, 2020
AstraZeneca, Cambridge, UK
AZD0364
1 min read
AstraZeneca oral reversible ERK1/2 kinase inhibitor
Search By Structure
- OI338
- PF07059013
- AZD0364
- PF-06843195
- TP0586352
- AZD4573
- “compound 42”
- “compound 12”
- BMS-986202
- pamiparib
- linrodostat
- SAR439859
- ACT-1004-1239
- “compound 1”
Molecules of the Month
2023
2022
2021
2020